Sugi Predict

Sugi Predict / Compounds / SCHEMBL1108260

SCHEMBL1108260

SCHEMBL1108260

C1=C/COCc2cc(ccc2OCCN2CCCC2)Nc2nccc(n2)-c2coc(c2)COC/1

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ JAK2 O60674 20/20 1.00
▸ FLT3 P36888 20/20 1.00
▸ TYK2 P29597 17/20 1.00
▸ JAK3 P52333 16/20 1.00
▸ JAK1 P23458 15/20 1.00
▸ CDK2 P24941 13/20 0.76
▸ CSF1R P07333 3/20 0.76
▸ CDK9 P50750 2/20 0.76
▸ CYP2D6 P10635 2/20 0.76
▸ CYP2C19 P33261 1/20 0.76
▸ CCNA2 P20248 6/20 0.75
▸ CCNA1 P78396 6/20 0.75
▸ GAK O14976 1/20 0.75
▸ STK16 O75716 1/20 0.75
▸ STK10 O94804 1/20 0.75
▸ MAP4K4 O95819 1/20 0.75
▸ PRKCB P05771 1/20 0.75
▸ LCK P06239 1/20 0.75
▸ PDGFRB P09619 1/20 0.75
▸ NQO2 P16083 1/20 0.75

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Ct-1578 SCHEMBL29456953 0.86 JAK2 (1.00) JAK2FLT3TYK2JAK3JAK1
Ct-1578 SCHEMBL1004926 0.86 JAK2 (1.00) JAK2FLT3TYK2JAK3JAK1
Ct-1578 SCHEMBL17594734 0.86 JAK2 (1.00) JAK2FLT3TYK2JAK3JAK1
Ct-1578 SCHEMBL29379113 0.86 JAK2 (1.00) JAK2FLT3TYK2JAK3JAK1
SCHEMBL1108226 0.86 JAK2 (1.00) JAK2FLT3TYK2JAK3JAK1
SCHEMBL1108255 0.85 JAK2 (1.00) JAK2FLT3TYK2JAK3JAK1
Pacritinib SCHEMBL31537559 0.85 JAK2 (1.00) JAK2FLT3TYK2JAK3JAK1
Pacritinib SCHEMBL29395340 0.85 JAK2 (1.00) JAK2FLT3TYK2JAK3JAK1
Pacritinib SCHEMBL1108221 0.85 JAK2 (1.00) JAK2FLT3TYK2JAK3JAK1
Pacritinib SCHEMBL30802892 0.85 JAK2 (1.00) JAK2FLT3TYK2JAK3JAK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11135227-B2 Oxygen linked pyrimidine derivatives CTI BIOPHARMA CORP. (US) 2021-10-05 — — US disclosed
EP-3854402-A1 TREATMENT OR PREVENTION OF TRANSPLANT REJECTION CTI Biopharma Corp. (US) 2021-07-28 — — EP disclosed
US-20210069199-A1 METHODS OF TREATING TRANSPLANT REJECTION SOBI, INC. 2021-03-11 — — US disclosed
US-20200071339-A1 OXYGEN LINKED PYRIMIDINE DERIVATIVES CTI BIOPHARMA CORP. (US) 2020-03-05 — — US disclosed
US-20170112846-A1 OXYGEN LINKED PYRIMIDINE DERIVATIVES CTI BIOPHARMA CORP. (US) 2017-04-27 — — US disclosed
US-20170112846-A1 OXYGEN LINKED PYRIMIDINE DERIVATIVES CTI BIOPHARMA CORP. (US) 2017-04-27 — — US disclosed
US-9573964-B2 Oxygen linked pyrimidine derivatives CTI BIOPHARMA CORP. (US) 2017-02-21 — — US disclosed
US-9573964-B2 Oxygen linked pyrimidine derivatives CTI BIOPHARMA CORP. (US) 2017-02-21 — — US disclosed
EP-1951729-B1 OXYGEN LINKED PYRIMIDINE DERIVATIVES CELL THERAPEUTICS INC (US) 2014-06-25 — — EP disclosed
US-20130172338-A1 OXYGEN LINKED PYRIMIDINE DERIVATIVES CELL THERAPEUTICS, INC. (US) 2013-07-04 — — US disclosed
US-20130172338-A1 OXYGEN LINKED PYRIMIDINE DERIVATIVES CELL THERAPEUTICS, INC. (US) 2013-07-04 — — US disclosed
US-8415338-B2 Oxygen linked pyrimidine derivatives CELL THERAPEUTICS, INC. (US) 2013-04-09 — — US disclosed
US-8415338-B2 Oxygen linked pyrimidine derivatives CELL THERAPEUTICS, INC. (US) 2013-04-09 — — US disclosed
US-20120196855-A1 OXYGEN LINKED PYRIMIDINE DERIVATIVES S*BIO PTE LTD. (SG) 2012-08-02 — — US disclosed
US-20120196855-A1 OXYGEN LINKED PYRIMIDINE DERIVATIVES S*BIO PTE LTD. (SG) 2012-08-02 — — US disclosed
US-8153632-B2 Oxygen linked pyrimidine derivatives S*BIO PTE LTD. (SG) 2012-04-10 — — US disclosed
US-8153632-B2 Oxygen linked pyrimidine derivatives S*BIO PTE LTD. (SG) 2012-04-10 — — US disclosed
US-20090075999-A1 OXYGEN LINKED PYRIMIDINE DERIVATIVES S*BIO PTE LTD. (SG) 2009-03-19 — — US disclosed
US-20090075999-A1 OXYGEN LINKED PYRIMIDINE DERIVATIVES S*BIO PTE LTD. (SG) 2009-03-19 — — US disclosed
WO-2007058627-A1 OXYGEN LINKED PYRIMIDINE DERIVATIVES S*BIO PTE LTD (SG) 2007-05-24 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210069199-A1 METHODS OF TREATING TRANSPLANT REJECTION JAK1, JAK2, JAK3 JAK2 2/4885FLT3 50/4885TYK2 34/4885
US-20090075999-A1 OXYGEN LINKED PYRIMIDINE DERIVATIVES DPYD, TK2, TK1 JAK2 468/4885FLT3 645/4885TYK2 960/4885
US-20130172338-A1 OXYGEN LINKED PYRIMIDINE DERIVATIVES DPYD, TK2, TK1 JAK2 468/4885FLT3 645/4885TYK2 960/4885
US-20170112846-A1 OXYGEN LINKED PYRIMIDINE DERIVATIVES DPYD, TK2, TK1 JAK2 468/4885FLT3 645/4885TYK2 960/4885
US-20120196855-A1 OXYGEN LINKED PYRIMIDINE DERIVATIVES DPYD, TK2, TK1 JAK2 468/4885FLT3 645/4885TYK2 960/4885
US-11135227-B2 Oxygen linked pyrimidine derivatives DPYD, TK2, TK1 JAK2 468/4885FLT3 645/4885TYK2 960/4885
US-20200071339-A1 OXYGEN LINKED PYRIMIDINE DERIVATIVES DPYD, TK2, TK1 JAK2 468/4885FLT3 645/4885TYK2 960/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.